Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Stuart H IsaacsonStanley FahnRajesh PahwaCaroline M TannerAlberto J EspayClaudia TrenkwalderCharles H AdlerRajiv PatniReed Johnson

Published in: Movement disorders clinical practice (2018)

These open-label data suggest ADS-5102 provides incremental reduction from baseline in MDS-UDPRS Part IV score in patients switched directly from amantadine IR, without exacerbating adverse events.

Keyphrases

open label
clinical trial
end stage renal disease
ejection fraction
phase ii
phase ii study
prognostic factors
phase iii
study protocol
squamous cell carcinoma
electronic health record
radiation therapy
big data
artificial intelligence
data analysis
double blind